ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
Foaming at mouth | 07.05.05.019; 08.01.03.070; 17.02.05.056 | - | - | - |
Skin plaque | 23.03.03.044 | - | - | - |
Lip pruritus | 07.05.05.021 | - | - | - |
Poor feeding infant | 14.03.02.022; 18.04.06.006 | - | - | - |
Pharyngeal paraesthesia | 17.02.06.035; 22.04.05.018 | - | - | - |
Administration site bruise | 08.02.04.016; 12.07.04.016; 23.03.11.023; 24.07.06.025 | - | - | - |
Administration site induration | 08.02.04.022; 12.07.04.022 | - | - | - |
Administration site pain | 08.02.04.029; 12.07.04.029 | - | - | - |
Agonal respiration | 02.11.05.001; 22.02.01.033 | - | - | - |
Fear of injection | 19.06.03.016 | - | - | - |
Fishbane reaction | 08.06.01.039; 15.03.04.020 | - | - | - |
Gait inability | 08.01.02.011; 17.02.05.069 | 0.000453% | | - |
Heavy menstrual bleeding | 21.01.03.005 | 0.001904% | | - |
Infusion related hypersensitivity reaction | 10.01.03.058; 12.02.05.055 | - | - | - |
Infusion site discolouration | 08.02.05.026; 12.07.05.026; 23.03.03.084 | - | - | - |
Injection site nerve damage | 08.02.03.066; 12.07.03.066 | - | - | - |
Intermenstrual bleeding | 21.01.01.015 | 0.002312% | | - |
Loss of therapeutic response | 08.06.01.041 | - | - | - |
Periorbital swelling | 06.08.03.032; 10.01.05.025; 23.04.01.025 | - | - | - |
Sensitive skin | 23.03.03.097 | - | - | - |
Similar reaction on previous exposure to drug | 08.06.01.046 | - | - | - |
Swelling of eyelid | 06.04.04.018; 10.01.05.026; 23.04.01.026 | - | - | - |
Therapeutic product effect delayed | 08.06.01.051 | - | - | - |
Therapeutic product effect incomplete | 08.06.01.052 | 0.000453% | | - |
Therapy non-responder | 08.06.01.063 | 0.000680% | | - |
Brain fog | 16.32.03.050; 17.02.05.077; 19.21.02.017 | - | - | - |